Artelo Biosciences (ARTL) vs CDT Equity (CDT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Artelo Biosciences is the larger company by market cap ($1.8 million vs $29,108), about 61.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTL | CDT |
|---|---|---|
| Share price | $3.26 | $0.718 |
| Market cap | $1.79M | $29.11K |
| 1-day change | -3.26% | -10.25% |
| P/E ratio (TTM) | — | 0.00 |
| EPS (TTM) | $-136.26 | $90,812.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $179.19 | $28,400.00 |
| 52-week low | $3.19 | $0.70 |
| Distance from 52-week high | -98.18% | -100.00% |
| Average volume | 480.92K | 188.27K |
| Shares outstanding | 547.77K | 40.54K |
| Employees | 7 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Artelo Biosciences is about 61.3 times larger than CDT Equity by market value ($1.79M vs $29.11K).
About Artelo Biosciences
ARTL stock →Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About CDT Equity
CDT stock →CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
ARTL vs CDT FAQ
Which is bigger, Artelo Biosciences or CDT Equity?
Artelo Biosciences (ARTL) is larger, with a market capitalization of $1.79M compared with $29.11K for CDT Equity (CDT).
Are Artelo Biosciences and CDT Equity in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.